3.36  0 (0%)		03-09 09:49
Open: 3.36 High: 3.36 Volume: 630		Pre. Close: 3.36 Low: 3.36 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	5.75	1-year :	7.06
Resists	First :	4.92	Second :	6.05
Pivot price	3.69
Supports	First :	3.09	Second :	2.57
MAs	MA(5) :	3.33	MA(20) :	3.92
	MA(100) :	0	MA(250) :	0
MACD	MACD :	-0.7	Signal :	-0.7
%K %D	K(14,3) :	16.2	D(3) :	13.7
RSI	RSI(14): 29.4
52-week	High :	8.35	Low :	3.09

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RGNT ] has closed above bottom band by 24.1%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	3.36 - 3.38	3.38 - 3.39
Low:	3.33 - 3.34	3.34 - 3.36
Close:	3.34 - 3.36	3.36 - 3.38

Regentis Biomaterials Ltd., a regenerative medicine company, develops tissue repair solutions that restore the health and enhance quality of life of patients. Its lead product candidate is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries and articular knee cartilage. The company focuses on developing orthopedic treatments using its Gelrin platform that is based on degradable hydrogel implants to regenerate damaged or diseased tissue. Regentis Biomaterials Ltd. was incorporated in 2004 and is based in Herzliya, Israel.

Tue, 24 Feb 2026
Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch - Finviz

Thu, 19 Feb 2026
She helped win FDA approval, then a $330M sale — now she’s CMO at Regentis - Stock Titan

Wed, 04 Feb 2026
Knee cartilage implant nears Europe launch as Regentis hires new CFO - Stock Titan

Thu, 29 Jan 2026
Knee cartilage gel trial adds NYU, Rush and more top U.S. hospitals - Stock Titan

Mon, 08 Dec 2025
Regentis Biomaterials Commences Trading on NYSE: Set to Transform Cartilage Repair Market with Off-the-Shelf Regenerative Product - newswire.com

Fri, 05 Dec 2025
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.